BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12599556)

  • 1. [The present status and future directions for standardization of PSA assays in PSA gray zone].
    Kurokawa K; Yamanaka H; Ishibashi M; Kano S; Arai Y
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():117-22. PubMed ID: 12599556
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
    Kuruma H; Egawa S
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Standardization of PSA assays].
    Kuriyama M
    Nihon Rinsho; 1998 Aug; 56(8):1998-2002. PubMed ID: 9750495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance of PSA-density: analysis in PSA gray zone cases].
    Ishizuka O; Iwata K; Igawa Y; Nishizawa O
    Hinyokika Kiyo; 2001 Sep; 47(9):611-3. PubMed ID: 11692595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Free/total ratio of prostate-specific antigen (PSA) for prostate cancer detection in patients with gray zone PSA level].
    Tanaka M; Murakami S; Igarashi T; Abe T; Suzuki K; Sekita N; Shimazaki J
    Hinyokika Kiyo; 1997 Dec; 43(12):855-60. PubMed ID: 9488932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Present status of serum total PSA assay and factors responsible for the inter-kit deviations].
    Kano S
    Nihon Rinsho; 2000 Jul; 58 Suppl():112-7. PubMed ID: 11022696
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Progress in standardization of total PSA immunoassays].
    Ishibashi M
    Rinsho Byori; 2004 Jul; 52(7):618-24. PubMed ID: 15344562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer].
    de La Taille A; Houlgatte A; Houdelette P; Berlizot P; Fournier R; Ricordel I
    Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The present status of standardization in serum total PSA measurement--a result of "Survey 2000" conducted by PSA ad hoc Committee of Japanese Urological Association].
    Kano S; Ishibashi M; Itoh Y;
    Rinsho Byori; 2001 Oct; 49(10):967-73. PubMed ID: 11769473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen: current status.
    Lukes M; Urban M; Záleský M; Zachoval R; Herácek J; Zdárský E
    Folia Biol (Praha); 2001; 47(2):41-9. PubMed ID: 11321246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prostate-specific antigen (PSA), PSA-ACT, free PSA and F/T].
    Kuriyama M
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():694-7. PubMed ID: 16149614
    [No Abstract]   [Full Text] [Related]  

  • 13. [PSA--monitoring the prostate. Diagnostic series: Early detection of prostatic carcinoma].
    Janssen K
    MMW Fortschr Med; 2000 Oct; 142(41):45. PubMed ID: 11085077
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF; Mensink HJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnosis and follow-up of prostate cancer patients using prostate specific antigen (PSA)].
    Kuriyama M; Uno H; Ueno K; Yamamoto N; Takahashi Y; Shinoda I; Ban Y; Kawada Y
    Hinyokika Kiyo; 1997 Jun; 43(6):453-6. PubMed ID: 9250498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSA as a screening test for prostate cancer.
    Crawford ED; DeAntoni EP
    Urol Clin North Am; 1993 Nov; 20(4):637-46. PubMed ID: 7505971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The influence of prostate volume on the diagnostic parameters related to PSA and clinicopathological features of prostate cancer].
    Kimura G; Kimata R; Saito Y; Yoshida K; Nishimura T
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():479-85. PubMed ID: 12599623
    [No Abstract]   [Full Text] [Related]  

  • 18. [Advancements in PSA-based screening for prostate cancer].
    Ito K
    Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of prostate specific antigen and gamma-seminoprotein ratio for diagnosing prostate cancer].
    Akino H; Suzuki Y; Okada K
    Nihon Rinsho; 1998 Aug; 56(8):2003-5. PubMed ID: 9750496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prostate cancer].
    Uchida K; Akaza H
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1469-74. PubMed ID: 11681260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.